CASE REPORTS
JOURNAL ARTICLE
REVIEW
Add like
Add dislike
Add to saved papers

Multifocal motor neuropathy.

Multifocal motor demyelinating neuropathy is an acquired immune-mediated neuropathy with distinctive clinical and electrophysiologic manifestations, and response to treatment. Clinically, it is characterized by slowly progressive asymmetrical predominantly distal weakness; unilateral wrist drop, grip weakness, and foot drop are the commonest initial manifestations. Electrophysiologic testing reveals multifocal motor demyelinating features. Persistent, localized, partial motor conduction block is the hallmark of the disorder. Results of sensory nerve conduction studies are generally normal, consistent with the lack of sensory symptoms and signs. Most patients show marked improvement in strength after treatment with intravenous human immunoglobulin or cyclophosphamide. The pathogenesis of the disease is not completely understood. An autoimmune pathogenesis is considered likely based on the beneficial response to immunomodulatory treatment and the presence of serum anti-GM1 ganglioside antibodies in affected patients.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app